<DOC>
	<DOCNO>NCT00023855</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness combine PS-341 doxorubicin treat patient advance solid tumor .</brief_summary>
	<brief_title>PS-341 Doxorubicin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose PS-341 combination doxorubicin patient advance solid tumor . - Determine qualitative quantitative toxic effect regimen patient . - Determine antitumor activity regimen patient . OUTLINE : This dose-escalation study PS-341 . Patients receive PS-341 IV 3-5 second day 1 , 4 , 8 , 11 ; doxorubicin IV 3-5 minute day 1 8 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos PS-341 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 3-31 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor curative treatment exist Measurable evaluable disease No brain metastasis primary brain tumor PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : MUGA least 45 % Other : No serious active infection No preexisting neuropathy grade 2 great No concurrent illness would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy No prior cumulative dose doxorubicin exceed 280 mg/m^2 Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : No concurrent investigational commercial agent treatment malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>